Samsung Biologics, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced on the 26th that it has signed a contract for contract manufacturing of pharmaceuticals worth 884 billion won with a European pharmaceutical company.
The contract amount is $63.78 million (approximately 884 billion won), which is about 1.94% of the company's consolidated revenue of 4.5473 trillion won last year. The contract duration is from today until Dec. 31, 2031, and the end date may change based on agreement between the two companies.
The company noted, "The contract counterparty will be disclosed on Dec. 31, 2031, due to confidentiality reasons, and there may be changes in the future."
※ This article has been translated by AI. Share your feedback here.